The herpesvirus thymidine kinases (TKs) are commonly used in gene therapy because their substrate specificity is distinct from that of cellular TK. They are able to phosphorylate a variety of non-toxic nucleoside analogues to their monophosphates, which are subsequently converted by cellular kinases to di-and triphosphates. These toxic forms cause the inhibition of cellular DNA polymerase and when incorporated into elongating DNA, result in the death of the cell.
Introduction
the treatment of brain and ovarian tumours in patients with end-stage cancer, leukaemia and AIDS (Marcel & Grausz, 1997; Roth & Cristiano, 1997) . However, the use of HSV-TK is limited by the toxicity of the nucleoside analogues, among others, hence the introduction of mutations into the TK gene so as to enhance its sensitivity to GCV and to acyclovir (ACV) (Black et al., 1996; Kokoris et al., 1999) .
The cytotoxicity of other enzyme/prodrug systems has also been investigated. A strong 'bystander' effect was observed in human breast cancer cells when a varicella zoster virus-TK (VZV-TK)-carrying vector was used along with BVDU as a prodrug (Grignet-Debrus & CalbergBacq, 1997) . Cazaux et al. (1998) compared the TK activity of three α-herpesviruses [HSV-1, VZV, Equine herpesvirus-4 (EHV-4)] and that of two γ-herpes-viruses [Epstein-Barr virus (EBV) and herpesvirus saimiri 2 (HVS-2)]. They tested the ability of these TKs to phosphorylate different nucleoside analogues such as AZT, D4T
(3′-deoxy-2′,3′-didehydrothymidine), DDI (dideoxyinosine) and 5-FUdR. When comparing γ-herpesvirus TKs with the α-herpesvirus TKs, the range of activation of all the analogues was found to be superior in the former. However, the EBV-TK does not phosphorylate GCV despite its thymidylate kinase activity (Gustafson et al., 1998) .
Murine herpesvirus strains 68 and 72, originally isolated from small free-living rodents in Slovakia (Blaskovic et al., 1980) were found to be closely related to γ-herpesviruses such as HVS, human herpesvirus-8 (HHV-8) and EBV (Efstathiou et al., 1990a,b; Sunil-Chandra et al., 1992; Reichel et al., 1994; Mistrikova et al., 1994; Virgin et al., 1997; Simas & Efstathiou, 1998) . Of late, both MHV-68 and MHV-72 infection of mice inducing lymphoproliferative diseases (LPD) have been intensively studied (SunilChandra et al., 1994a; Mistrikova et al., 1996a,b; Smee et al., 1997) .
MHV-68 thymidine kinase gene was mapped by Pepper et al. (1996) and its ORF was compared with 15 herpesvirus TKs. The sequence revealed the presence of all six conserved herpesvirus TK regions. The consensus nucleotide binding site (GXXGXGK), in which the second glycine is replaced by alanine, was present only in MHV-TK. Northern blot analysis of MHV-68-infected cells showed the expression of a 2.6 kb early TK message, and its functional activity was proved in an in vitro transcription-translation system (Pepper et al., 1996) .
As yet, the ability of murine γ-herpesvirus TK to phosphorylate nucleoside analogues has not been reported, despite the ACV effect on murine γ-herpesvirus-68 infected mice (Sunil-Chandra et al., 1994b) and the inhibition of MHV-68 replication by other nucleoside analogues in vivo and in vitro (Neyts & De Clercq, 1998) .
We investigated the sensitivity of MHV-72-TK to different nucleoside analogues in order to determine if any MHV-TK/prodrug system could be effective and less toxic than the systems previously described. The aim of our study was to characterize the MHV-72-TK relative to the HSV-1-TK, which is most frequently used in gene therapy against cancer and HIV infection. We selected GCV and BVDU to investigate the MHV-72-TK/prodrug system. Previous findings in which TKs encoded by γ-herpesviruses seemed to be more efficient than α-herpesvirus TKs in the activation of certain nucleoside analogues (except that of GCV) (Cazaux et al., 1998) , led us to also investigate the phosphorylation of AZT and 5-FUdR by MHV-72-TK.
Materials and Methods
Compounds GCV, AZT, BVDU and 5-FUdR were purchased from Sigma. The compounds were prepared in a sterile cell culture medium for in vitro assays.
Virus and cells
Murine γ-herpesvirus strain 72 was obtained from J Mistrikova of the Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia. Normal Murine Mammary Gland cell line (NMuMG, ATTC CRL-1636) was propagated in Dulbeco's modified Eagle's medium (DMEM, GIBCO) supplemented with 10% (v/v) of fetal calf serum (FCS). MHV-72 clone 8 originally grown in VERO cells (Blaskovic et al., 1980) was adapted to NMuMG cells. Pools of MHV-72 prepared in NMuMG were aliquoted and stored at -70°C. A rat fibroblastoid cell line derived from the 5′-bromodeoxyuridine-resistant subclone RAT1 with disrupted cellular TK (RAT2, ATCC CRL 1764) was propagated in the same medium. A fibroblastoid tumour cell line was derived from the fibrosarcoma developed in BALB/c mouse 300 days after intranasal infection with MHV-72 (Mistrikova et al., 1996a) . The fibrosarcoma cells went through more than 30 passages cultivated in RPMI medium containing 10% (v/v) of FCS with antibiotics and the cell line thus obtained was termed 'NAD'. Several different methods [Southern blot, PCR, RT-PCR and Gardella electrophoresis (Gardella et al., 1984) ] were used to confirm that the mouse tumour cell line NAD harboured no virus (unpublished data). Tumours developed 1 month after subcutaneous injection of NAD cells into nude BALB/c mice or immunocompetent BALB/c mice (Raslova, personal communication).
Purification of viral DNA
Virus stock was prepared by infecting the NMuMG cell line with MHV-72 at a low multiplicity (0.1 PFU/cell). Five days post-infection, the clarified virus was centrifuged at 60000×g for 3 h at 4°C and then purified by centrifuga-
tion (80000×g for 1 h at 4°C) through linear sucrose gradient (10/60%). The purified virus was resuspended in 2×NPE (pH 7.5) (0.2 M NaCl, 20 mM Na 2 HPO 4 .2H 2 O, 1 mM NaH 2 PO 4 , 2 mM EDTA) and incubated with RNAase A (100 µg/ml) for 30 min at 37°C. It was then treated for 4 h at 60°C with proteinase K and SDS (100 µg/ml and 1%, respectively). The DNA was isolated by two phenol-chloro-form extractions and by ethanol precipitation.
Cloning of MHV72 -TK gene
Viral DNA digested by BamHI was separated in 0.4% agarose gel electrophoresis. The BamHI/E fragment containing the TK gene was purified (Wizard DNA Clean-Up System, Amersham), cloned into pUC19 according to standard methods (Maniatis et al., 1982) 
Sequencing of MHV72 TK gene
MHV-72-TK gene was sequenced using OmniBase DNA cycle sequencing System (Promega) as well as T7 Sequenase 7-deaza-dGTP DNA sequencing kit (Amersham Life Science) with universal pUC/M13 forward (24-mer) and reverse (22-mer) primers; another five forward and six reverse TK-specific primers designed according to MHV-68 TK sequence data were used. The sequence of TK gene was compared with that of strain MHV-68 using DNASIS software.
DNA transfection
Stable transfectants expressing MHV-72-TK gene were prepared by transfection of RAT2 cells by the modified calcium phosphate precipitation method of Chen and Okayama (1987) . 4×10 5 cells were transfected with 10 µg of pTarget/MHV-72-TK DNA. Seventy-two hours after incubation in CO 2 at 37°C with a change of medium after the first 12 h, the cells were trypsinized and seeded onto a 24-well plate (7×10 4 cells per well). They were cultivated for 2 weeks in selective medium with 600 µg of G418 per ml (GIBCO BRL). The individual G418-resistant colonies were harvested and pooled to yield the RAT2/MHV72-TK cell population. Two selected cell line clones (RAT2/MHV-72-TK I and II) were then tested by cultivation in DMEM supplemented with 1×HAT. In parallel, transfection of RAT2 cells with the recombinant vector pBK/HSV-1-TK (constructed and kindly provided by Adrian Chrastina, Institute of Virology SAS, Slovakia) was performed and cell lines I and II, expressing RAT2/HSV-1-TK, were prepared separately.
Determination of TK expression by RT-PCR assays
MRNAs were isolated from 3.10 6 RAT2/MHV-72-TK I, II and RAT2/HSV-1-TK I, II cells using Oligotex Direct mRNA Mini Kit (Qiagen) while mRNA, isolated from non-transfected RAT2 cells, was used as a negative control. About one third of mRNAs eluted in 40 µl were denaturated for 5 min at 65°C and reverse transcribed in 20 µl reaction mixture containing a 1×M-MLV RT buffer; 0.25 mM of each dNTP; 1 µM of individual reverse primer; 40 U of RNAsin and 200 U of M-MLV reverse transcriptase (Promega) at 37°C for 20 min, then at 42°C for 45 min and finally at 90°C for 3 min. Individual PCRs were then performed with the whole RT mixture in 100 µl of standard PCR reaction buffer (GIBCO BRL) containing 0.2 µM of the individual forward primer and 5 U of recombinant Taq DNA polymerase. The TKR and TKF primers for amplification of MHV-72-TK and PCR conditions were used as described above. Transcription of HSV-1-TK gene, was proved in RT-PCR assay with the reverse primer TK3: 5′-GGA CAG GTT ATT TAC CCT GTT TCG G-3′ (from nt 46994 to 46970) and the forward primer TK4: 5′-TCA GTT AGC CTC CCC CAT CTC CC-3′ (from nt 46669 to 46692) designed according to sequence data of HSV1 strain 17 (Acc. N°K03541). This yielded 277 bp product under the following conditions: 40 cycles (each consisted of 94°C for 45 s, 56°C for 45 s and 72°C for 1 min) with one final extension step at 72°C for 10 min. MHV-72 DNA and HSV-1 DNA from strain 17 were used as positive controls. PCR products were separated by electrophoresis in a 0.8% agarose gel (MHV-72-TK PCR product) or 1.5% agarose gel (HSV-1-TK PCR product) and visualized under UV light after staining with ethidium bromide.
In vitro thymidine kinase enzyme assay cells of RAT2, RAT2/MHV-72-TK I and RAT2/HSV-1-TK II cell lines were plated in triplicate per well on 96-well dishes in DMEM medium supplemented with 10% (v/v) of FCS. After 2 days of incubation, the medium was changed and varying concentrations of GCV (0-360 µM), AZT (0-375 µM), 5-FUdR (0-36 µM) and BVDU (0-50 µM) were independently added to the various cultures. The cell lines were incubated for 5 days at 37°C in CO 2 and the drug-containing media was changed daily. The individual inhibition of cell growth caused by the nucleoside analogues was determined by measuring cell viability using the CellTiter 96 Non-Radioactive cell proliferation assay (Promega) based on the cellular conversion of a tetrazolium salt into a formazan product that is easily detected with the ELISA plate reader (MULTISKAN MCC/340P). The toxicity of nucleosides was expressed as the inhibitory concentration required to reduce the survival of cells by 50% (IC 50 ).
The bystander effect assay mediated by MHV-72-TK/5-FUdR system Cell killing mediated by the bystander effect was studied on mouse tumour cell line NAD by cultivating with RAT2 cells expressing MHV-72-TK (cell line I) in varying proportions (0, 1, 5, 10, 20, 30, 40 and 50% of RAT2/MHV-72-TK I cells). The cells were plated in triplicate on 96-well plates at a density of 10 4 cells/well. They were then incubated for 2 days at 37°C in DMEM, as above; 5-FUdR was added to the medium at a concentration of 10.8 µM.
The incubation was continued for 5 days with a daily change of the drug containing medium. Finally, the cell killing assay, based on the MTT colorimetric cell proliferation assay, was performed as described above. Thy into the cell DNA during a 5-h incubation. We found that RAT2/MHV-72-TK I and RAT2/HSV-1-TK II cell lines exhibited comparable TK activity (Table 1) . These cell lines were chosen for in vitro cell killing assay.
Results

Cloning and sequencing
MHV-72-TK-expressing cells are resistant to GCV
Ganciclovir, a nucleoside analogue of guanosine, is known to be efficiently phosphorylated by the HSV-TK, but data concerning MHV-TK are lacking. We compared the GCV sensitivity of RAT2/MHV-72-TK I and RAT2/HSV-1-TK II cell lines. The cell killing experiments were performed at different concentrations of GCV (0-360 µM). The GCV concentration capable of killing 50% of the cell population (IC 50 ) was determined. No growth inhibition was observed for RAT2 cells expressing the MHV-72-TK gene or for non-transfected RAT2 cells (containing neither endogenous nor exogenous TK) in the presence of GCV ( Figure 3 ; Table 2 ).
RAT2/MHV-72-TK-expressing cells appeared to be relatively insensitive to GCV. The IC 50 values for GCV cytotoxicity of RAT2/MHV-72-TK and RAT2 cells were >360 µM, whereas the RAT2 cells expressing HSV-1-TK grew poorly even at relatively low concentration of GCV (IC 50 =9.7 µM). These results suggest that MHV-72-TK probably does not phosphorylate GCV.
AZT, BVDU and 5-FUdR dose response
We compared the AZT, BVDU and 5-FUdR sensitivity of RAT2/MHV-72-TK I and RAT2/HSV-1-TK II cell lines to determine if the expression levels of MHV-72-TK and HSV-1-TK would be affected by these nucleoside analogues. No growth inhibition was observed in cell lines tested in the presence of AZT or BVDU, using different concentrations of AZT (from 0 to 375 µM) and of BVDU (from 0 to 50 µM), nor was it observed in RAT2 nontransfected cells (Figure 3 ; Table 2 ). These results indicate that in the range of concentration used, RAT2 cells expressing MHV-72-TK or HSV-1-TK were not sensitive to the toxic activities of AZT and BVDU. Similarly, the non-transfected RAT2 cells were not sensitive to AZT and BVDU, with more than 50% of the cells surviving, up to a concentration of 375 and 50 µM, respectively.
Cell killing experiments performed at different concentrations of 5-FUdR (from 0 to 36 µM) showed that the RAT2/MHV-72-TK I cell line was sensitive to 5-FUdR (IC 50 =2.1 µM). RAT2/HSV-1-TK II cell line was less sensitive (IC 50 =32.2 µM), but the drug's inhibitory effect was somewhat stronger than in non-transfected cells. Only a slight inhibition of non-transfected RAT2 cell growth was observed when the 5-FUdR concentra- tions greater than 11 µM were used (Figure 3) . At the concentrations used, the MHV-72-TK expression levels affected the 5-FUdR dose response but not AZT, GCV and BVDU. HSV-1-TK expression levels slightly affected the GCV and 5-FUdR dose response but not AZT and BVDU.
Bystander killing of mouse tumour cells (NAD) mediated by RAT2/MHV-72-TK-expressing cell line and 5-FUdR
To determine if the bystander effect can operate between two mammalian cell types using 5-FUdR as a prodrug, cell killing assays were performed in the co-cultures of mouse tumour cells (NAD) and RAT2 cells expressing MHV-72-TK. Non-transfected RAT2 cells were used as a negative control. As we have shown, 10.8 µM 5-FUdR decreased the survival of RAT2/MHV-72-TK I cells to 14% ( 
Discussion
One approach to the treatment of cancer and a wide variety of other diseases is based on the expression of killer or suicide exogenous enzymatic activity in tumour cells. In our study, we investigated a new combination of the suicide H Raslova et al.
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©2000 International Medical Press gene/prodrug system focusing on the thymidine kinase of murine γ-herpesvirus 72. Our results showed that the MHV-72-TK sequence does not differ from that of strain 68 (Pepper et al., 1996) . Previous studies have shown the ability of ACV to reduce the replication of MHV-68 in immunocompetent mice at the primary infection site (Sunil-Chandra et al., 1994b) . Several nucleoside and nucleotide analogues, for example, cidofovir, fialuridine and ACV, were studied in the lethal immunosuppression model in BALB/c mouse (Smee et al., 1997) . The results of these studies, and the inhibition of MHV-68 replication in Vero cells by GCV, ACV and brivudin (Neyts & De Clercq, 1998) , suggested that MHV-TK could phosphorylate these antiviral prodrugs. We studied: (i) the enzyme activity of MHV-72-TK expressed in TK-defective mammalian cells in vitro versus that of HSV-1-TK; (ii) the ability of MHV-72-TK to phosphorylate nucleoside analogues in these cells; and (iii) the bystander killing of mouse tumours cells mediated by MHV-72-TK expressing cells in conjunction with 5-FUdR.
(i) Our results demonstrated that MHV-72-TK, cloned in a mammalian expression vector and expressed in rat fibroblastoid cells with a disrupted cellular TK gene (RAT2 cells), exhibited an enzyme activity comparable to that of HSV-1-TK.
(ii) We compared the sensitivity of two cell lines, expressing either MHV-72-TK or HSV-1-TK, to one purine and three pyrimidine nucleoside analogues.
It is well known that GCV is a prodrug that is effectively phosphorylated by HSV-1-TK. However, we did not observe cell growth inhibition even when high doses of GCV were administered to cells expressing MHV-72-TK, whereas the growth of those expressing HSV-1-TK was inhibited with low doses of GCV. This supports previous data showing that some pyrimidine analogues are more efficient in systems expressing γ-herpesvirus TKs than in those expressing α-herpesvirus TKs. This was not evident when using the purine analogue GCV (Cazaux et al., 1998) . Similar results were obtained by Gustafson et al. (1998) in EBV-TK/GCV (ACV) systems. The EBV-TK has been shown to phosphorylate neither GCV nor ACV, despite the fact that such antiviral drugs were reported to be effective for therapy of the EBV lytic disease, oral hairy leukoplakia (OHL) (Herbst et al., 1989; Newman & Polk, 1987) , and despite the fact that GCV has been shown to be experimentally phosphorylated in an EBV lymphoblastoid cell line (Lin et al., 1986) . The most probable hypothesis is that they are phosphorylated by other mechanisms, possibly by the product of the protein kinase gene conserved among human herpesviruses Smith & Smith, 1989) . Human cytomegalovirus (HCMV) does not encode a thymidine kinase, but its protein kinase (UL97), as well as the homologue in VZV (ORF 43), can phosphorylate GCV (Littler et al., 1992; Koyano et al., 1996) . The gene coding for the EBV protein kinase (BGLF4) (Lin et al., 1986) was also identified in the MHV-68 genome (ORF 36) (Virgin et al., 1997) . We therefore suggest that this gene is probably responsible for both GCV and ACV phosphorylation in the treatment of acute and latent MHV infection (Neyts & De Clercq, 1998) .
BVDU was the other antiviral prodrug investigated. The cytostatic effect of BVDU on tumour cells transfected by HSV-1, HSV-2 and VZV-TKs has been previously reported (De Clercq et al., 1979; Balzarini et al., 1987 Balzarini et al., , 1993 Grignet-Debrus & Calberg-Bacq, 1997) . However, we did not observe the cytotoxic effect of this drug in the rat fibroblastoid cells, which constitutively expressed either MHV-72-TK or HSV-1-TK, and which were treated with different BVDU concentrations. It is probable that cellular enzymes in our system were unable to convert monophosphate prodrugs into their triphosphate forms. It is also probable that the cellular thymidylate synthase (TS), a target of BVDU action, is not efficiently inhibited by this drug in the cell system we used.
We observed no growth inhibition of either MHV-72-TK-or HSV-1-TK-expressing RAT2 cells in the presence of AZT, irrespective of the concentration. Despite the fact that MHV-72 belongs to γ-herpesviruses, its TK sensitivity to AZT is not comparable to that of EBV or HVS. This is not surprising, considering the difference between EBV-TK and HVS-TK as expressed either in prokaryotic or in eukaryotic systems. The AZT dose causing complete growth inhibition of cells expressing HVS-TK is 30 times (in prokaryotic cells) and 3 times (in eukaryotic cells) high-er than the dose required for cells expressing EBV-TK. Since HVS is supposed to be more closely related to MHV than to EBV (Virgin et al., 1997) , one could expect a relatively low sensitivity of MHV-72-TK to AZT.
We decided to investigate further with the 5-FUdR prodrug. 5-FUdR and 5′-fluorouracil (5-FU) are common chemotherapeutic drugs in the treatment of advanced colorectal cancer (Van Laar et al., 1996) . Both drugs are cytotoxic as a consequence of the inhibition of TS by the metabolite 5′-fluoro-2′-deoxyuridine 5′-monophosphate (Fd-UMP). TS is indispensable in the de novo synthesis of dTMP and its inhibition occurs through the formation of a stable ternary complex (among the Fd-UMP; 5,10-methylenetetrahydrofolate and TS) (Kitchens et al., 1999) . The intracellular formation of this was shown to be dependent on the presence of the thymidine kinase (Washtien & Santi, 1979) . In our work we demonstrated that MHV-72-TK-expressing cells are the most sensitive to 5-FUdR among four nucleoside analogues tested. The ability of MHV-72-TK to metabolize this drug into toxic 5d-UMP is at least 16 times higher than that of HSV-1-TK.
(iii) The extreme 5-FUdR sensitivity of MHV-72-TKexpressing RAT2 cells led us to test whether the bystander effect could be induced between rat and mouse cells. The anti-tumour activity of 5-FUdR was shown earlier to be 20 to 200 times that of 5-fluorouridine or 5-fluorouracil against human and murine tumour cell lines. Because 5-FUdR is rapidly converted to 5-FU, relatively high doses of 5-FUdR must be administered for optimal efficiency. Yet, high doses of 5-FUdR cause severe toxicity (Yamada et al., 1998) . Teratogenic doses of 5-FUdR produce haematomas with subsequent skeletal malformations of chicken embryos and birth defects (Patel et al., 1996) . We demonstrated the efficient bystander killing of mouse tumour cells (NAD) mediated by only 1% of cells expressing MHV-72-TK and by 5-FUdR at a low concentration (10.8 µM). These results suggest that the bystander effect can be induced by short-term cocultivation of heterologous cell types, one of which expresses the viral TK enzyme when no transduction takes place. The increased amount of cells expressing MHV-72-TK indeed enhanced the bystander effect, but not dramatically. It is likely that there is a population of tumour cells resistant to the observed bystander effect. However, when higher ratios of cells expressing TK were used, the low concentration of 5-FUdR chosen could have had a limiting impact on the entire mechanism and thus resulted in a relatively slight increase of the bystander effect. Furthermore, in gene therapy the bystander killing process requires the TK transduction of a small portion of tumours cells so as to make them sensitive to prodrugs, thus enabling successful eradication of tumours (Ishii-Morita et al., 1997; Cazaux et al., 1998; Boucher et al., 1998; Rubsam et al., 1999) . Thus, the elucidation of transduction mechanisms, the bystander effect itself and the investigation of novel and/or mutant TK genes could contribute to a more effective killing of tumour cells with lower concentrations of drugs that are generally toxic to normal cells. We can raise the hypothesis that transduction of tumour cells with MHV-72-TK may enhance the bystander killing effect. We suggest that this new MHV-72-TK/5-FUdR system be used in order that lower 5-FUdR doses can be administered, which would then decrease systemic toxicity and other side-effects of cancer treatment.
